about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersTranscriptional regulator PRDM12 is essential for human pain perceptionFunctional requirement of aquaporin-5 in plasma membranes of sweat glands.Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskImmunolocalization of AQP9 in liver, epididymis, testis, spleen, and brain.Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermisIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Epsilon haemoglobin specific antibodies with applications in noninvasive prenatal diagnosis.Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparinRUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements.A distinct population of clonogenic and multipotent murine follicular keratinocytes residing in the upper isthmus.Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.Expression of the RAI gene is conducive to apoptosis: studies of induction and interference.Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriersIdentification of six new susceptibility loci for invasive epithelial ovarian cancer.An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersCommon variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.Enforced expression of PPP1R13L increases tumorigenesis and invasion through p53-dependent and p53-independent mechanisms.Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation CarriersA nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskCommon alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.Identification of four novel susceptibility loci for oestrogen receptor negative breast cancerMultiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.Severe prenatal renal anomalies associated with mutations in HNF1B or PAX2 genes.Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish pheochromocytoma/paraganglioma patients.Dataset on gene expression profiling of multiple murine hair follicle populationsValidation of diagnostic codes for Charcot-Marie-Tooth disease in the Danish National Patient RegistryUpdate of PAX2 mutations in renal coloboma syndrome and establishment of a locus-specific database.
P50
Q21144874-AE384D0A-8CC3-43E9-BC17-11C66E7091B2Q24337786-EDAFF52D-807F-4DA5-9916-5EDA1B0C8518Q24531363-BAE64997-6F39-4375-B7F6-6F3EE1DA22D5Q27008356-316406A6-1BB7-4312-8BAE-04E45513BE99Q27876229-72ECE733-3159-492E-AC3F-A49AE5617045Q28211891-DFCC21BB-5DCB-4606-9566-7A400A5317C2Q30252854-BE1E3AD1-0F5B-45FD-8248-4F713829618CQ30374367-FD1E7D40-9CDB-47D9-A3FC-A09A7A101164Q31043651-40442F49-8BC6-41E1-B666-23396C8C00D7Q33487714-26BEC710-D98C-4388-B3E9-5AFB10C552C4Q34081557-1501C91A-BA7D-4759-8BC9-CFE05F3ACA74Q34213455-C5B05CE8-E4FD-4ECA-B5B1-D8421514F5DFQ34235512-3C2D88A5-B14D-43F1-9914-5A1EEE309782Q34394665-7BB77959-F3D9-4739-AB58-339D333C0A29Q34637788-0F2D8D7E-EB36-40B8-B5AA-777C182C3954Q34963894-CC262FFF-D8E1-43BA-964F-65E7D1EBBC6FQ35022825-8C7C7ABD-540C-4EF9-ACA7-4D6DEE1BB56AQ35155449-DBC3FA4D-7FD5-4544-BB87-E69F2611C7A2Q35242849-8AD02508-0650-44B8-B8FB-7E2E2C32CC5EQ35523236-8DEFF4D8-9B65-42EC-A7E6-0807BF701472Q35541663-33698644-86ED-4464-8F19-5BCE96CEAA5EQ35618307-F837BACC-BD3E-4C2D-8EAB-B2BCF8A7663FQ35870067-FD085FCD-F7D2-4F3F-B034-899D2331BC7BQ35889575-23CE66C3-908E-4F70-BA41-32EE3D4E2359Q35893960-95EBB922-5092-43AF-8282-0096BC3FEFE2Q35957703-06B05ACB-001E-417A-9B66-2A2F8BC6D144Q36086247-120F5171-8C8E-4C2A-9138-347FFCA301F8Q36087170-58BE0D93-77B9-42D0-A1CB-EFBC5DD7D547Q36152991-08670EAF-DA68-4A56-B4BC-F0B03491B0F6Q36178189-9F7CC3F0-4A9C-448A-A3A0-C4D4499BD233Q36356727-883398AD-7820-4552-917C-61F6A5790E5BQ36720814-EDCAE2C9-67A4-41EA-B34F-091029C87388Q36839777-FB215228-3B39-4B83-B77C-B8361DF77D57Q36859142-A231FE6B-A5C9-4D30-A618-C527CFE9F81BQ36897003-648F7559-506F-48F9-A010-3B7CBE15C463Q36980350-1B25101C-AA4F-4750-B42E-2C85877161D0Q36982205-4AA0BE68-ED81-439E-B0FD-E363CA876B46Q37270873-B115DF73-0096-45A0-9ED8-30903FDE0A45Q37441596-D3127441-3A3C-41D4-953C-A1E4D5C2D624Q37972823-8A344391-A21C-449E-B84E-2BEEC303FF0D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Uffe Birk Jensen
@ast
Uffe Birk Jensen
@en
Uffe Birk Jensen
@es
Uffe Birk Jensen
@nl
Uffe Birk Jensen
@pt
Uffe Birk Jensen
@sl
type
label
Uffe Birk Jensen
@ast
Uffe Birk Jensen
@en
Uffe Birk Jensen
@es
Uffe Birk Jensen
@nl
Uffe Birk Jensen
@pt
Uffe Birk Jensen
@sl
altLabel
Jensen UB
@en
prefLabel
Uffe Birk Jensen
@ast
Uffe Birk Jensen
@en
Uffe Birk Jensen
@es
Uffe Birk Jensen
@nl
Uffe Birk Jensen
@pt
Uffe Birk Jensen
@sl
P1053
E-6066-2017
P106
P1153
35902139300
P31
P496
0000-0002-6205-6355